Illumina, Inc. (ILMN), a biotechnology company, on Tuesday reported preliminary results for the fourth quarter and fiscal 2025 above analysts' expectations.
For the fourth quarter of 2025, the company expects net profit of $2.14 to $2.17 per share, with adjusted earnings of $1.27 to $1.30 per share. On average, 17 analysts polled forecast the firm to earn $1.21 per share for the quarter. Analysts' estimates typically exclude special items.
For the final quarter, Illumina anticipates revenue of around $1.155 billion, compared with analysts' estimate of $1.1 billion.
For the fourth quarter of 2024, the company had reported a net income of $1.17 per share, with an adjusted profit of $0.86 per share, on revenue of $1.104 billion.
For fiscal 2025, Illumina anticipates net income of $5.42 to $5.45 per share, with adjusted earnings of $4.76 to $4.79 per share. Analysts, on average, forecast the company to earn $4.7 per share.
For fiscal 2025, the company expects revenue of $4.34 billion, higher than Street view of $4.28 billion.
For fiscal 2024, Illumina had reported a net loss of $7.69 per share, with adjusted earnings per share of $2.45, on revenue of $4.372 billion.
The company intends to release its annual earnings report on February 5.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.